Literature DB >> 11700776

Impact of allergic rhinitis treatment on quality of life.

A Tripathi1, R Patterson.   

Abstract

Allergic rhinitis is a chronic inflammatory disorder of the nasal passages. It affects approximately 20% of the population, is a significant health and economic burden, and severely impairs quality of life. Two main instruments, Medical Outcomes Study 36-Item Short Form health survey (SF-36) and Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) have been used to assess quality of life in patients with allergic rhinitis. Antihistamines, corticosteroids, anticholinergic agents, decongestants, cromoglycates, and immunotherapy are used to treat patients with allergic rhinitis. Of these, antihistamines and intranasal corticosteroids are the most efficacious and frequently utilised medications. Studies have demonstrated improvements in quality of life with both of these medications in patients with allergic rhinitis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11700776     DOI: 10.2165/00019053-200119090-00001

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  77 in total

1.  Clinical comparison of systemic methylprednisolone acetate versus topical budesonide in patients with seasonal allergic rhinitis.

Authors:  W J Pichler; T Klint; M Blaser; W Graf; K Sauter; S Weiss; K Witschi
Journal:  Allergy       Date:  1988-02       Impact factor: 13.146

2.  Impairment of function by antihistamines.

Authors:  H Druce
Journal:  Ann Allergy       Date:  1990-05

3.  Diagnosis and management of rhinitis: complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology.

Authors:  M S Dykewicz; S Fineman; D P Skoner; R Nicklas; R Lee; J Blessing-Moore; J T Li; I L Bernstein; W Berger; S Spector; D Schuller
Journal:  Ann Allergy Asthma Immunol       Date:  1998-11       Impact factor: 6.347

Review 4.  Levocabastine: an effective topical treatment of allergic rhinoconjunctivitis.

Authors:  M M Janssens; G Vanden Bussche
Journal:  Clin Exp Allergy       Date:  1991-05       Impact factor: 5.018

Review 5.  Intranasal fluticasone propionate. A reappraisal of its pharmacology and clinical efficacy in the treatment of rhinitis.

Authors:  L R Wiseman; P Benfield
Journal:  Drugs       Date:  1997-05       Impact factor: 9.546

6.  A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis.

Authors:  P H Ratner; J H van Bavel; B G Martin; F C Hampel; W C Howland; P R Rogenes; R E Westlund; B W Bowers; C K Cook
Journal:  J Fam Pract       Date:  1998-08       Impact factor: 0.493

7.  Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving.

Authors:  J G Ramaekers; M M Uiterwijk; J F O'Hanlon
Journal:  Eur J Clin Pharmacol       Date:  1992       Impact factor: 2.953

8.  Intranasal fluticasone propionate is more effective than terfenadine tablets for seasonal allergic rhinitis.

Authors:  J van Bavel; S R Findlay; F C Hampel; B G Martin; P Ratner; E Field
Journal:  Arch Intern Med       Date:  1994 Dec 12-26

9.  Long-term safety of budesonide nasal aerosol: a 5.5-year follow-up study.

Authors:  U Pipkorn; J Pukander; J Suonpää; J Mäkinen; N Lindqvist
Journal:  Clin Allergy       Date:  1988-05

10.  Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal allergic rhinitis.

Authors:  E Bronsky; P Boggs; S Findlay; S Gawchik; J Georgitis; H Mansmann; L Sholler; J Wolfe; E Meltzer; R Morris
Journal:  J Allergy Clin Immunol       Date:  1995-08       Impact factor: 10.793

View more
  16 in total

1.  Are the birch trees in Southern England a source of Betula pollen for North London?

Authors:  C A Skjøth; M Smith; J Brandt; J Emberlin
Journal:  Int J Biometeorol       Date:  2008-11-11       Impact factor: 3.787

2.  Prolonged effect of allergen sublingual immunotherapy to grass pollen.

Authors:  Andrzej Bozek; Marek Jąkalski; Monika Jonska-Golus; Agata Filipowska-Gronska; Jerzy Jarząb; Giorgio Walter Canonica
Journal:  Hum Vaccin Immunother       Date:  2018-09-14       Impact factor: 3.452

3.  The relationship between hypertension and health-related quality of life: adjusted by chronic pain, chronic diseases, and life habits in the general middle-aged population in Japan.

Authors:  Masami Kitaoka; Junko Mitoma; Hiroki Asakura; Olando Enoch Anyenda; Thao Thi Thu Nguyen; Toshio Hamagishi; Daisuke Hori; Fumihiko Suzuki; Aki Shibata; Masae Horii; Hiromasa Tsujiguchi; Yuri Hibino; Yasuhiro Kambayashi; Yoshiaki Hitomi; Naoto Shikura; Nakamura Hiroyuki
Journal:  Environ Health Prev Med       Date:  2016-02-18       Impact factor: 3.674

Review 4.  Levocetirizine: a review of its use in the management of allergic rhinitis and skin allergies.

Authors:  Philip I Hair; Lesley J Scott
Journal:  Drugs       Date:  2006       Impact factor: 9.546

5.  Epidemiology and burden of nasal congestion.

Authors:  Michael Stewart; Bj Ferguson; Len Fromer
Journal:  Int J Gen Med       Date:  2010-04-08

6.  Pharmacokinetics and safety of ebastine in healthy subjects and patients with renal impairment.

Authors:  Robert J Noveck; Richard A Preston; Suzanne K Swan
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

7.  Does the duration and time of sleep increase the risk of allergic rhinitis? Results of the 6-year nationwide Korea youth risk behavior web-based survey.

Authors:  Jeoung A Kwon; Minjee Lee; Ki-Bong Yoo; Eun-Cheol Park
Journal:  PLoS One       Date:  2013-08-27       Impact factor: 3.240

8.  Clinical utility and patient adherence with ebastine for allergic rhinitis.

Authors:  Giorgio Ciprandi
Journal:  Patient Prefer Adherence       Date:  2010-10-14       Impact factor: 2.711

9.  Septal injection in comparison with inferior turbinates injection of botulinum toxin A in patients with allergic rhinitis.

Authors:  Sayed Mojtaba Abtahi; Sayed Mostafa Hashemi; Sayed Hamidreza Abtahi; Bagher Bastani
Journal:  J Res Med Sci       Date:  2013-05       Impact factor: 1.852

10.  Reduced work/academic performance and quality of life in patients with allergic rhinitis and impact of allergen immunotherapy.

Authors:  A Roger; E Arcalá Campillo; M C Torres; C Millan; I Jáuregui; E Mohedano; S Liñan; P Verdu; N Rubira; M Santaolalla; P González; A Orovitg; E Villarrubia
Journal:  Allergy Asthma Clin Immunol       Date:  2016-08-11       Impact factor: 3.406

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.